Related Experiment Video
Updated: Feb 3, 2026
11:01
Moderate Prenatal Alcohol Exposure and Quantification of Social Behavior in Adult Rats
Published on: December 14, 2014
10.3K
Challenges in Prenatal Treatment with Dexamethasone
Bonnie McCann-Crosby1, Frank Xavier Placencia2, Oluyemisi Adeyemi-Fowode3
1Division of Pediatric Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA,
Pediatric Endocrinology Reviews : PER
|October 30, 2018
Summary
Prenatal dexamethasone can prevent virilization in female fetuses with classic congenital adrenal hyperplasia (CAH). However, its use is controversial due to unnecessary exposure and potential adverse effects, necessitating careful ethical consideration.
Area of Science:
- Endocrinology
- Genetics
- Maternal-Fetal Medicine
Background:
- Classic congenital adrenal hyperplasia (CAH) results from 21-hydroxylase deficiency, leading to elevated androgens and potential virilization of female genitalia.
- Prenatal dexamethasone is effective in preventing virilization if initiated before 7-9 weeks of gestation.
Purpose of the Study:
- To review the short- and long-term outcomes of prenatal dexamethasone exposure in fetuses and pregnant women.
- To discuss the ethical considerations surrounding prenatal dexamethasone treatment for CAH.
- To provide current practice recommendations for managing CAH risk during pregnancy.
Main Methods:
- Review of existing literature on prenatal dexamethasone treatment for CAH.
- Analysis of fetal and maternal outcomes.
- Ethical framework application.
Main Results:
- Prenatal dexamethasone is effective in preventing virilization but diagnosis is only confirmed later in pregnancy.
- A significant proportion of fetuses are unnecessarily exposed, as only 1 in 8 fetuses are affected by classic CAH.
- Concerns exist regarding potential adverse outcomes from in utero steroid exposure.
Conclusions:
- Prenatal dexamethasone carries significant ethical considerations due to potential risks and low treatment efficacy for all exposed fetuses.
- Careful evaluation of risks and benefits is crucial for guiding treatment decisions.
- Updated practice recommendations are needed to address the complexities of prenatal CAH management.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
997
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
997
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:22Alzheimer's Disease: Treatment
952
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
952
01:26Anticholinesterase Agents: Poisoning and Treatment
1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K
01:28Angle Closure Glaucoma: Treatment
1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K